In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Bellerophon (NASDAQ: BLPH), with a price target of $3. The company’s shares closed yesterday at $0.60, close to its 52-week low of $0.47.
Fein commented:
“Our new price target of $3/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing. Bellerophon Therapeutics, Inc.”
According to TipRanks.com, Fein is a 3-star analyst with an average return of 2.5% and a 46.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Currently, the analyst consensus on Bellerophon is a Moderate Buy with an average price target of $3.
See today’s analyst top recommended stocks >>
Based on Bellerophon’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.47 million. In comparison, last year the company had a GAAP net loss of $3.93 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bellerophon Therapeutics, Inc clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases.
Read More on BLPH:
